The researchers also projected that newly diagnosed MM cases will increase by 70.8% by 2045 — from about 188,000 cases in 2022 to about 321,000 cases in 2045. The number of deaths due to MM is ...

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients. These ...

Odds are usually set to make this impossible, so you often need to use a profit boost or use multiple sportsbooks with different odds for the same event to pull this off. Backdoor Cover ...

There has also been exciting new research into a new classification of breast cancer called HER2-“low” which means the tumors have lower levels of HER2, but do not meet the classic definition for HER2 ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...

Recently, however, researchers have looked to further expand this definition to include patients that have a minimal amount of HER2 expression but do not meet the classic definition for HER2-positive ...

are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...

1Division of Myeloma, Department of Medicine ... Cooperative efforts were required to obtain and analyze clinical trial data from multiple sponsors and to determine the best approach to analysis with ...